Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) closed its previously announced underwritten public offering, issuing 9,387,896 ordinary shares, including 1,293,103 shares from the underwriters’ fully exercised option, and pre-funded warrants to purchase up to 525,897 ordinary shares. Ordinary shares were priced at $14.50 and pre-funded warrants at $14.499 each, reflecting a $0.001 exercise price.
According to Crescent, the offering generated approximately $143.7 million in gross proceeds before underwriting discounts, commissions and expenses. All securities were sold by the company under an effective Form S-3 shelf registration. Jefferies, TD Cowen, Guggenheim Securities and Cantor served as joint book-running managers, with LifeSci Capital as passive book-runner.
Positive
- Underwritten equity raise with gross proceeds of approximately $143.7 million
- Full exercise of underwriters’ option for 1,293,103 additional shares
- Demand included both ordinary shares and 525,897 pre-funded warrant allocations
- All securities sold by Crescent, directly strengthening corporate cash resources
Negative
- Issuance of 9,387,896 new shares plus up to 525,897 warrant-linked shares increases outstanding equity base
- Gross proceeds of $143.7 million are subject to underwriting discounts, commissions and offering expenses
News Explained
Existing holders face potential ownership dilution from the closed financing; gross proceeds equal 1,447.1 days of first-quarter operating cash use.
With the offering closed, all securities were sold by Crescent Biopharma; the financing therefore adds potential share count and can reduce existing holders’ percentage ownership if the warrants are exercised.
The pre-funded warrants convert into ordinary shares when exercised, making that ownership effect conditional on exercise rather than on the warrant’s sale alone.
On the same basis, the offering’s gross proceeds equal
For the remaining economics, the release leaves net proceeds and use of proceeds unstated; the final prospectus supplement is the named filing for final size, price, and fees.
Sources and calculations
- Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants (2026-07-16)
- Dilution (2026-07-14)
- Pre-funded warrant (2026-07-14)
- Prospectus supplement purpose (2026-07-14)
- Crescent Biopharma first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $143,700,000 / ($8,937,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $189,163,000 / ($8,937,000 / 90) = [object Object]
News Market Reaction – CBIO
In the Jul 17 session, CBIO declined 2.38%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.1% during that session. Argus tracked a trough of -11.7% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Offering pricing | Neutral | +2.4% | Priced underwritten offering of shares and pre-funded warrants with defined gross proceeds. |
| Jul 14 | Offering launch | Neutral | +2.4% | Commenced underwritten public offering of ordinary shares and pre-funded warrants under S-3 shelf. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent offering-related announcements for Crescent have coincided with positive share price moves rather than selloffs.
Key Terms
pre-funded warrants financial
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has closed its previously announced underwritten public offering of 9,387,896 ordinary shares, including 1,293,103 ordinary shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares were sold to the public at a price of
Jefferies, TD Cowen, Guggenheim Securities and Cantor acted as joint book-running managers for the offering. LifeSci Capital acted as passive book-running manager for the offering.
The securities described above were offered by Crescent pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 10, 2026. A final prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus are accessible through the SEC’s website at www.sec.gov. The offering was made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
